Kailera makes history with record-breaking $625m IPO
Obesity biotech Kailera Therapeutics has set its sights on the US public market through an upsized $625m IPO, marking one of the largest public offerings in the sector’s history.
In a 16 April statement, Kailera announced it’d be offering all 39,062,500 of its shares to prospective buyers at a price of $16 per unit – at the top end of the suggested price detailed in its S-1 filing – with the company expected to commence trading on the Nasdaq under the ticker “KLRA” on 17 April.
Underwriters will also have 30 days to buy another 5,859,375 shares at $16, leaving another $92.8m up for grabs by the company.
Through this IPO, Kailera expects to secure $625m in gross proceeds, which eclipses the expected $458.7m in net proceeds detailed in the S-1 form, making it one of the largest IPOs in biotech history since Moderna’s $604m public market debut in 2018.
With this new capital in hand, Kailera hopes to take another step closer to the burgeoning obesity market dominated by Eli Lilly and Novo Nordisk – pouring $650m into funding its three-trial, late-stage KaiNETIC programme for lead obesity injectable, ribupatide, into Q2 2028, as per the company’s S-1 filing.
As the oral obesity market picks up steam, the biotech will also dedicate $150m to the development of its once-daily, ribupatide pill, which will help fund Phase III trials involving the therapy.
While ribupatide is currently a key focal point for Kailera, the biotech is also looking to harness these funds to push its other obesity therapies down the pipeline – including small molecule glucagon-like peptide 1 receptor agonist (GLP-1RA) pill, KAI-7535, and ‘triple G’ agonist, KAI-4729, which are currently in mid and early-stage development, respectively.
This IPO comes fairly soon after the company’s debut in October 2024, which saw the Bain-backed biotech make a splash with a $400m Series A. Since then, the company has focused on developing its in-licensed obesity assets from prominent Chinese dealmaker, Jiangsu Hengrui Pharmaceuticals, which could see the biotech compete for glory on the ex-China obesity market.
While Kailera’s public offering has caused a significant stir in the industry, there have been multiple other IPOs that have also been catching the headlines.
This includes precision proteomic specialist Alamar Biosciences, which recently upsized its 11.25 million share public offering to $17 to reach a total value of over $191m.
Seaport and Hemab have also set their sights on the public market, though both companies are yet to share further financial details on their offerings.
